Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Istradefylline
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Marvel Biosciences Extends Collaboration with iBraiN Institute on Rett Syndrome
Details : The collaboration aims to advance clinical development of the company's early-stage product MB204 (istradefylline) for the treatment of Rett syndrome.
Brand Name : MB-204
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Istradefylline
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?